StockTipsArenaBeta

BUY Wockhardt Limited — Kunal Bothra

BUYWockhardt Limited
Wockhardt share price target & all analyst calls

byKunal BothraHorizon: NA (inferred Swing (≤2wk))26 May 2026via ET Now

Entry₹1,700Stated
Target₹1,750
Total upside +2.94% (call closed)
Stop loss₹1,670-1.76% risk
Exit—No position was opened
ExpiredNA
Follow Kunal Bothra for new calls(30% target hit, 275 closed calls)Get alertsWatch WOCKPHARMA for new buy/sell callsGet alertsSee 108 active Swing picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

As of 22 Oct, 8:45 am IST
2 supporting0 opposing
Supports the BUY call (2)

Wockhardt Limited received U.S. FDA approval for ZAYNICH (cefepime and zidebactam), a novel intravenous antibiotic for treating complicated urinary tract infections in adults.

NSE · Press Release·30 May · 1w ago

(opens in new tab)

Wockhardt's ZAYNICH® (Zidebactam/Cefepime) has received marketing authorization from the Indian drug regulator for treating complicated urinary tract infections.

NSE · Press Release·28 May · 2w ago

(opens in new tab)
Neutral / worth noting (0)

Nothing found in this tip’s window yet.

Weighs against the BUY call (0)

Nothing found in this tip’s window yet.

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Wockhardt

All analyst calls on Wockhardt

More from Kunal Bothra

Every call and its outcome